Pirbright, UK & Nivelles, Belgium – Thursday, March 13, 2025
The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), part of The Pirbright Institute, a world-leading center for the research and surveillance of viral diseases in livestock and zoonotic viruses, has selected Quantoom Biosciences’ Ntensify® mini to advance its mRNA and saRNA vaccine development at its UK site. The adoption of this production technology will support preclinical research efforts in developing innovative vaccine candidates to combat infectious diseases in livestock.
CVIM has been actively engaged in mRNA and saRNA vaccine research, collaborating with Quantoom Biosciences since last year to develop vaccine candidates for sheep, specifically targeting Peste des Petits Ruminants Virus (PPRV). Building on the outstanding results of this partnership, the collaboration is now expanding to design additional saRNA-based vaccine candidates (between others, against Bluetongue virus, a major threat to livestock health).
The Ntensify mini is a research-grade mRNA and saRNA production platform that will enable cost-effective, high-quality RNA synthesis and purification, significantly accelerating the institute’s ability to develop next-generation vaccines.
Prof Bryan Charleston, Director of The Pirbright Institute: “We are committed to exploring the utility of RNA vaccines and compare their performance with other vaccine deliver platforms currently under investigation at CVIM. The Ntensify mini will allow us to rapidly explore different RNA vaccine configurations, initially in vitro and then in vivo in the natural livestock host species.”
José Castillo, CEO of Quantoom Biosciences, commented: “We are proud to see The Pirbright Institute adopt our Ntensify technology for their groundbreaking work in animal health. Their investment in the Ntensify mini demonstrates the growing recognition of RNA-based vaccines as a transformative tool in livestock disease prevention. We look forward to continuing this successful collaboration and supporting Pirbright in advancing their vaccine development efforts.”
About The Centre for Veterinary Vaccine Innovation and Manufacturing at The Pirbright Institute
The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) aims to accelerate the development of vaccines and vaccine platforms for use in livestock. Using the specialist expertise and facilities CVIM works towards translating innovative ideas from the laboratory to commercially feasible products, by optimising candidate vaccines and vaccine production processes. With a particular focus on neglected and emerging disease of livestock, and zoonotic diseases, CVIM supports global food security, pandemic preparedness, and One Health. More info: https://www.pirbright.ac.uk/cvim
